SPOTLIGHT -
Ms Kuntz is the assistant managing editor of Psychiatric Times.
The Psychiatric Pipeline in Review: Quarter 2, 2025
What disease states are most prominently featured in recent research? Learn more in this exclusive article.
Ketamine Safe for the Treatment of Patients With Eating Disorders: In Conversation With Elizabeth Wassenaar, MD, MS, DFAPA, CEDS-C
New research reveals ketamine's safe use for treating eating disorders, offering hope for patients with comorbid treatment-resistant depression.
Presenting Our July Theme: Geriatric Psychiatry
Explore essential insights and best practices in geriatric psychiatry in our July theme! Submit your insights, tips, and case studies centered on healthy aging for older adults.
Positive Results From the Phase 2b Study of BPL-003 in Patients With Treatment-Resistant Depression
New clinical trial results reveal BPL-003's rapid and durable antidepressant effects, paving the way for innovative treatments in treatment-resistant depression.
FDA Requires New Label Warning of Weight Loss Risk in Pediatric Patients Taking Extended-Release Stimulants for ADHD
The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals.
June in Review: Updates on the Psychiatric Treatment Pipeline
Check out the pipeline updates from June!
ALTO-203 Fails to Primary Efficacy Endpoint in Phase 2 Major Depressive Disorder Trial
Alto Neuroscience's ALTO-203 trial reveals mixed results, highlighting potential biomarkers for targeted depression treatment despite missing primary efficacy goals.
COMP360 Psilocybin for Treatment-Resistant Depression: Positive Phase 3 Efficacy Data
Compass Pathways reports significant progress in psilocybin research, showing promise for treatment-resistant depression in a pivotal phase 3 trial.
The Loss of a Vital LGBTQ+ Suicide Prevention Resource: In Conversation With AFSP’s Christine Yu Moutier, MD
Christine Yu Moutier, MD, the chief medical officer of the AFSP, speaks about the impact of losing LGBTQ+ tailored crisis support via 988, and strategies to better support vulnerable youth.
The Week in Review: June 16-20
Stay informed with this week's highlights, including more on the clozapine REMS, the termination of the 988 LGBTQ+ specific services, and the intersection of sex and psychiatry!
Loss of 988 Hotline Services Tailored to LGBTQ+ Youth
LGBTQ+ youth face increased suicide risks as vital support services are cut, prompting urgent calls for Congress to reverse this dangerous decision.
New Positive 12-Month Extension Data: Ecopipam for Tourette Syndrome in Pediatric Patients
Ecopipam shows promise as a safe, effective treatment for Tourette syndrome in children and adolescents, significantly reducing tic severity and improving quality of life.
FDA Officially Eliminates Clozapine REMS
The FDA's removal of clozapine REMS enhances access to treatment, while new educational initiatives empower clinicians to improve patient care.
Senators Reintroduce Access to Prescription Digital Therapeutics Act
US Senators have reintroduced The Access to Prescription Digital Therapeutics Act to increase access to prescription digital therapeutics and decrease barriers to care.
Facts Over Fiction: The Current State of Psychiatry
The government has always played an important role in health care. Recent changes, however, are actively altering the practice of medicine and are posed to have a deep and lasting psychiatric impact on patients. Learn more here.
Presenting Our June Theme: Diversity
Championing diverse voices: check out our June theme! We want to hear about your insights, tips, and case studies.
Insights From the 2025 APA Annual Meeting
Discover key insights from the APA Annual Meeting, highlighting advancements in lifestyle psychiatry, ADHD treatment, and innovative suicide prevention models.
May in Review: Updates on the Psychiatric Treatment Pipeline
Check out the pipeline updates from May!
Treatment Comparison: Somnolence/Sedation With Dopamine Partial Agonists vs D2 Receptor Antagonists
Recent research reveals dopamine partial agonists significantly reduce somnolence in major depressive disorder and schizophrenia compared with D2 receptor antagonists.
New Data: Cariprazine Adjunctive to Antidepressant Therapy for Anhedonia Symptoms
Cariprazine shows promise as a long-term adjunctive treatment for anhedonia in major depressive disorder, according to new poster data presented at the ASCP Annual Meeting.
Positive Phase 2 Results on NBI-1117568 for Schizophrenia Presented at 2025 ASCP Annual Meeting
Neurocrine Biosciences reveals promising phase 2 results for NBI-1117568, a novel treatment for schizophrenia, showing significant symptom improvement over placebo.
Social Psychiatry and Culturally Relevant Psychotherapy at the APA Annual Meeting
Vincenzo Di Nicola discusses the importance of pluralism in social psychiatry and the need for culturally relevant psychotherapy at the 2025 APA Annual Meeting.
The Usefulness of Mental Health Apps and Digital Therapeutics: Thoughts From the APA Annual Meeting
How many apps do you use on your phone? John Luo, MD, a technology expert shares his thoughts on their usefulness at the 2025 APA Annual Meeting.
Ketamine-Assisted Psychotherapy: Updates From the 2025 APA Annual Meeting
Ketamine-assisted psychotherapy: enhancing healing through emotional support and insight-driven therapy for depression.
Improving Your Media Skill Set: Armed With Knowledge
Psychiatry must embrace media to combat misinformation, shared Mena Mirhom, MD, FAPA, at the 2025 APA Annual Meeting.
Will AI Replace Psychiatrists? Thoughts From the APA Annual Meeting
Will AI replace psychiatrists and mental health clinicians? John Luo, MD, thinks not, despite the many technological advances of today.
Challenges for Older Adults: Insights From a Geriatric Psychiatrist at the APA Annual Meeting
Badr Ratnakaran, MBBs, highlights the rising stressors for older adults, emphasizing the urgent need for improved health care and support systems.
The Value of Networking at the APA Annual Meeting
The APA Annual Meeting: a valuable career opportunity.
Protecting Your Online Reputation: Advice From a Technology Expert
At the APA Annual Meeting, John Luo, MD, discussed the importance of managing your online reputation and privacy in today's digital landscape for future opportunities.
Promoting Mental Health Through Media: Messages From the APA Annual Meeting
Mena Mirhom, MD, the Psychiatric Times Media & Psychiatry Section Editor, discusses media training for psychiatry fellows, enhancing their skills to effectively communicate and combat misinformation.